CTLA4 and neoplasm: However, additional combination of MUC1 LCP-mRNA with an anti-CTLA4 antibody was needed to enhance CD8+ T cell recruitment, inhibit the tumor-promoting STAT3 pathway, and further enhance anti-tumor responses in the murine triple negative breast cancer cells, in vivo [59].